

# Alberta COVID-19 Immunization Policy

Effective February 2021  
Revised January 2023

Superseded

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without written permission of Alberta Health, Government of Alberta.

All information in the Alberta COVID-19 Immunization Policy (ACIP) is presented for public health and health sector purposes only.

The ACIP is presented with the intent that it is readily available for non-commercial informational use by health providers, organizations and other entities involved in the distribution and administration of COVID-19 vaccine and is not intended for use by the general public. Except where prohibited, the ACIP may be reproduced in part or in whole and by any means without charge or further permission from the government of Alberta provided that:

- users exercise due diligence in applying the ACIP; and
- the Government of Alberta is identified as the source of the ACIP.

Users are responsible for any changes and modifications they make to the ACIP and in any event, use of the ACIP is not a substitute for the proper exercise of professional judgment by the user in applying the ACIP. If modifications are made to the ACIP by anyone other than by the Government of Alberta, the modified ACIP must clearly indicate that it is not an official version of the original ACIP, and must not be represented as having been made in affiliation with or with the endorsement of the Government of Alberta.

This publication is issued under the Open Government Licence – Alberta (<http://open.alberta.ca/licence>).

For further information for health professionals on the use of this policy contact:

[health.imm@gov.ab.ca](mailto:health.imm@gov.ab.ca)

Health and Wellness Promotion Branch

Public Health and Compliance Division

Alberta Health

Alberta COVID-19 Immunization Policy | Alberta Health

© 2023 Government of Alberta | January 2023

---

## Contents

Introduction .....	4
Requirements for participation in the COVID-19 Immunization Program .....	4
Client eligibility.....	5
Reporting Adverse Events Following Immunization (AEFIs) .....	7
Vaccine storage and handling .....	7
Alberta Vaccine Inventory (AVI) management system.....	8
Wastage mitigation strategies .....	8
Vaccine preparation.....	9

Superseded

## Introduction

The Alberta COVID-19 Immunization Policy (ACIP) sets out the requirements for the delivery of the COVID-19 Immunization Program.

Alberta's COVID-19 Immunization Program supports the Canadian COVID-19 Immunization Program goals to:

- Enable as many Canadians as possible to be immunized as quickly as possible against COVID-19, while ensuring that high risk populations be prioritized;
- Minimize serious illness and overall deaths while preserving health system capacity; and
- Reduce transmission to protect high-risk population.

Alberta's COVID-19 Immunization Program objectives are to:

- Provide a safe and effective COVID-19 vaccine for all Albertans for whom the vaccine is licensed and recommended;
- Allocate, distribute and administer COVID-19 vaccine as efficiently, equitably and effectively as possible;
- Collaborate with stakeholders and build vaccine confidence; and,
- Monitor the safety and effectiveness of COVID-19 vaccines.

## Requirements for participation in the COVID-19 Immunization Program

Health practitioners must be compliant with the [Immunization Regulation](#), Alberta Health immunization policies and the following requirements:

- [Immunization Regulation](#)
  - All immunization events must be reported electronically to the Provincial Immunization Repository (Imm/ARI).
  - Follow the strict storage and handling requirements for the vaccines.
  - Report adverse reactions following immunizations as they become aware.
- Vaccine inventory must be reconciled in the Alberta Vaccine Inventory System (AVI) **every Monday by 9pm**.
- Follow the product monographs for information that includes:
  - Storage and Handling;
  - Vaccine preparation; and
  - Timeframe for use once thawed, reconstituted and/or vial punctured.
- Must have protocols in place for the management of anaphylaxis.
- Provide each client with complete informed consent (includes an overview of the vaccine, a discussion on the risks/benefits, side effects and verifying immunization history to determine if the client has received COVID-19 vaccine).
- Offer the client an immunization record.
- Include information to each client on participation in CANVAS active surveillance process for adverse events following immunization.
- Alberta Health Services (AHS) will coordinate outreach immunization services.
  - As coordinated by AHS, community pharmacies can assist in offering outreach immunization services in seniors' congregate care facilities (e.g., long-term care, designated supportive living, supportive living).
- COVID-19 vaccine must not be transferred between pharmacies or physician medical clinics unless directed by Alberta Health.
  - Transferring vaccine increases risks of cold chain excursions.
  - Vaccine inventory cannot be tracked when transfers occur without Alberta Health's assistance.

## Client eligibility

Albertans 6 months of age and older are eligible for COVID-19 vaccines. Non-Alberta residents who live, work, go to school or travel in the province are also eligible to receive vaccine. Individuals without an active Alberta Health Care number must book an appointment with AHS by calling Health Link at 8-1-1.

### Primary series

#### For Albertans without eligible immunocompromising conditions

The majority of Albertans 6 months of age and older are eligible for two doses of the COVID-19 vaccine as part of their primary series, except for children 6 months to 4 years of age that receive the Pfizer-BioNTech vaccine which requires a three-dose primary series.

#### For Albertans with eligible immunocompromising conditions

The majority of Albertans 6 months of age and older with eligible immunocompromising conditions are eligible for three doses of the COVID-19 vaccine as part of their primary series, except for children 6 months to 4 years of age with eligible immunocompromising conditions that receive the Pfizer-BioNTech vaccine which requires a four-dose primary series.

### Fall/Winter 2022-2023 Booster Dose

Albertans 12 years of age and older who have completed a primary series are recommended to receive a bivalent booster dose during the 2022-2023 fall/winter season regardless of the number of booster doses previously received.

Albertans 5 to 11 years of age are recommended to receive a bivalent booster dose if they have not already received a monovalent booster dose. Albertans 5 to 11 years of age with certain [underlying medical conditions](#) may receive a bivalent booster dose even if they have previously received a monovalent booster dose.

For specific eligibility criteria, see the [Alberta Health COVID-19 vaccine](#) and the [Alberta Immunization Policy](#) webpages.

### Reporting immunizations to Imm/ARI

As of January 1, 2021, the Immunization Regulation requires that health practitioners electronically submit a report respecting immunizations to Imm/ARI within 7 days in accordance with the [Immunization Data Submission and Response Guidelines](#).

**For COVID-19 vaccine, immunization events should be reported as soon as possible and must be reported within 7 days.**

Required reporting can be accomplished through immunization web services, Immunization Direct Submission Mechanism (IDSM) or Alberta Blue Cross (ABC) claims.

- Alberta Health is working with vendors to integrate immunizing partners' point of care systems to Imm/ARI.
- Providers can [register to access the IDSM by following these instructions](#).

For pharmacists: COVID-19 immunizations are batched into Imm/ARI through the ABC claims data that pharmacists submit. IDSM is for privately funded vaccine only.

**REASON CODES**

Listed in order of priority

Reason code	Descriptor	Pin (Pharmacy use)
03	Health Care Workers not including LTC/DSL	10000003 (Pfizer/BioNTech) 20000003 (Moderna) 21800003 (Moderna bivalent)
44	LTC/DSL Staff	10000044 (Pfizer/BioNTech) 20000044 (Moderna) 21800044 (Moderna bivalent)
22	LTC/DSL Resident	10000022 (Pfizer/BioNTech) 20000022 (Moderna) 21800022 (Moderna bivalent)
70	Other congregate care living settings (e.g. senior lodges, corrections, group homes)	10000070 (Pfizer/BioNTech) 20000070 (Moderna) 21800070 (Moderna bivalent)
02	Advanced age (65+)	10000002 (Pfizer/BioNTech) 20000002 (Moderna) 21800002 (Moderna bivalent) 20003002 (Moderna booster half dose 50 mcg) 11700002 (Pfizer bivalent)
66	Other Risk (Individuals with underlying health conditions, including eligible immunocompromising conditions)	10000066 (Pfizer/BioNTech) 20000066 (Moderna) 21800066 (Moderna bivalent) only 18+ 20003066 (Moderna booster half dose 50 mcg)
72	12 years to 64 years of age	10000072 (Pfizer/BioNTech) 20000072 (Moderna) 21800072 (Moderna bivalent) only 18+ 20003072 (Moderna booster half dose 50 mcg) 11700072 (Pfizer bivalent)
73	COVID-19 in-school immunization program	N/A
74	COVID-19 additional dose for travel	10000074 (Pfizer/BioNTech) 20000074 (Moderna)
75	5 years to 11 years of age	11000075 (Pediatric Pfizer/BioNTech) 21000075 (Moderna 50mcg dose for 6 years to 11 years of age)
76	6 months to 4 years of age	N/A
98	Research (AH approved)	10000098 (Pfizer/BioNTech) 20000098 (Moderna)

# Reporting Adverse Events Following Immunization (AEFIs)

Health practitioners shall ensure that adverse events following immunization (AEFIs) are reported to AHS within 3 days of becoming aware.

## Passive Surveillance

Passive AEFI surveillance systems rely on the client voluntarily reporting an AEFI for further investigation and reporting.

- As part of informed consent, clients are provided information on expected reactions following immunization and are encouraged to call Health Link or their health practitioner if there are events outside the expected reactions.
- As per the [Immunization Regulation](#) these events are to be reported to the AHS Provincial AEFI team, which determines if the events meet the reporting criteria for submitting the AEFI to Alberta Health.

## Active Surveillance

Active AEFI surveillance involves proactively collecting data from clients who have received the vaccine through phone calls or surveys. The [CANVAS – COVID Study](#) is optional, and usually takes less than one minute to complete online. Enrollment eligibility can be found [here](#).

Enrollment should occur at the time of immunization (and no later than 7 days since most recent dose) and clients should be provided with the attached QR code from the printable poster which can be scanned, or by providing the link: <https://canvas-covid.ca/>.



COVID Vaccine QR  
Handout\_18DEC2020 |

The [Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization](#) policy includes case definitions and reporting requirements for COVID-19 vaccine, the process for 'active and passive surveillance' of AEFIs following COVID-19 vaccine, and the list and description of adverse events of special interest to be monitored following COVID-19 immunization. The COVID-19 policy is a supplement to the current [Adverse Events Following Immunization \(AEFI\) Policy](#).

See [Alberta Health Services information](#) on how to report an adverse event following immunization.

## Vaccine storage and handling

The requirements for the storage, handling and transportation of all COVID-19 vaccines are outlined in the:

- [Alberta Vaccine Storage and Handling for COVID-19 Vaccine](#)
- [Alberta Vaccine Storage and Handling Policy for Provincially Funded Vaccine](#)
- Product monographs (see Vaccine preparation section below for specific product links)

## Temperature Excursions

- Health practitioners must report temperature excursions to the vaccine manufacturer within 24 hours.
  - The [Alberta Vaccine Storage and Handling for COVID-19 Vaccine](#) includes manufacturer contact information (including after hours).
- Any vaccine that is determined not viable must be discarded according to the health practitioners' standard of practice and must be entered into AVI as wasted using the correct reason.

## Alberta Vaccine Inventory (AVI) management system

The AVI Management System is the administrative system that supports the vaccine inventory management within the Alberta Immunization Program and is integral to the management of the COVID-19 Immunization Program. It is a secure online information system used by Alberta for the ordering, receiving and reconciliation of vaccines in the province.

All immunizing partners must receive the COVID-19 vaccine they have been shipped in AVI and are required to reconcile inventory using AVI **every Monday** by 9 pm.

All vaccine delivery sites must have at least one provider (up to 2) who will be responsible for AVI. Access and [training](#) will be provided by Alberta Health.

## Wastage mitigation strategies

It is imperative that every effort is made to reduce COVID-19 vaccine wastage.

- Follow the storage and handling requirements to minimize vaccine wastage due to improper transportation, storage or handling.
- When possible, group individuals to be immunized on the same day. However, some wastage will be inevitable to ensure that no immunization opportunity is missed.

Superseded



# Vaccine preparation

Each COVID-19 vaccine has unique preparation requirements that health practitioners must be aware of.

## Pfizer-BioNTech (Comirnaty)

### Alberta Health Biological Product Information

- [Pfizer-BioNTech Monovalent \(12+\)](#)
- [Pfizer-BioNTech Monovalent \(5 to 11 years\)](#)
- [Pfizer-BioNTech Monovalent \(6 months to 4 years\)](#)
- [Pfizer-BioNTech Bivalent Original and Omicron BA.4/BA.5 \(12+\)](#)
- [Pfizer-Bio-NTech Bivalent Original & Omicron BA.4/BA.5 \(5 to 11years\)](#)

### Product Monographs

- [Pfizer-BioNTech Monovalent COVID-19 vaccine](#) (includes pediatric formulations)
- [Pfizer-BioNTech Bivalent COVID-19 vaccine](#)

### Other Resources

- [The S.T.E.P.S. to Pfizer-Biotech COVID-19 vaccination](#)
- [Information about Low Dead-Volume Syringes and/or needles for Pfizer-BioNTech COVID-19 vaccine](#)
- [Pfizer- BioNTech COVID-19 Vaccine Information for Canadian Health Care Professionals](#)

## Moderna (Spikevax)

### Alberta Health Biological Product Information

- [Moderna Monovalent \(12+\)](#)
- [Moderna Monovalent \(6 to 11 years\)](#)
- [Moderna Monovalent \(6 months to 5 years\)](#)
- [Moderna Bivalent Original and Omicron BA.1 \(18+\)](#)

### Product Monographs

- [Moderna COVID-19 Monovalent Vaccine](#) (includes pediatric formulations)
- [Moderna COVID-19 Bivalent Vaccine](#)

### Other Resources

- [Spikevax Dosing & Administration and Storage & Handling](#)

## Novavax (Nuvaxovid)

- [Alberta Health Biological Product Information for COVID-19 Vaccine-Novavax](#)
- [Novavax – COVID-19 Vaccine \(Product Monograph\)](#)

## Janssen

- [Alberta Health Biological Product Information for COVID-19 Vaccine-Janssen](#)
- [Janssen COVID-19 Vaccine \(Product Monograph\)](#)